{"id":4424,"date":"2019-03-26T06:39:54","date_gmt":"2019-03-26T06:39:54","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/?post_type=study_trials&#038;p=4424"},"modified":"2019-03-26T06:39:54","modified_gmt":"2019-03-26T06:39:54","slug":"resultados-a-longo-prazo-apos-a-interrupcao-do-tratamento-com-inibidores-de-braf-a-base-de-vemurafenibe-na-doenca-de-erdheim-chester-love","status":"publish","type":"study_trials","link":"https:\/\/www.erdheim-chester.org\/pt\/study_trials\/long-term-outcome-after-vemurafenib-braf-inhibitors-interruption-in-erdheim-chester-disease-love\/","title":{"rendered":"Resultados a longo prazo ap\u00f3s a interrup\u00e7\u00e3o do tratamento com vemurafenibe\/inibidores de BRAF na doen\u00e7a de Erdheim-Chester (LOVE)"},"content":{"rendered":"<p><strong>Objetivo do estudo:<\/strong> Pacientes com ECD em tratamento com vemurafenibe parecem apresentar doen\u00e7a est\u00e1vel. Este estudo avalia a possibilidade de interrup\u00e7\u00e3o do tratamento. Outros inibidores de BRAF, como o dabrafenibe, foram recentemente propostos para o tratamento de histiocitoses com muta\u00e7\u00e3o no BRAF. A interrup\u00e7\u00e3o do tratamento com outros inibidores de BRAF tamb\u00e9m deve ser avaliada prospectivamente.<\/p>\n<p><strong>Pesquisador principal:<\/strong> Julien Haroche, M.D., Ph.D., Hospital Piti\u00e9-Salp\u00eatri\u00e8re, Paris, FRAN\u00c7A<\/p>\n<p><strong>Informa\u00e7\u00f5es de contato:<\/strong> Telefone: +33 1 42 17 80 37 E-mail: julien.haroche@psl.aphp.fr<\/p>\n<p><strong>Envolvimento solicitado do paciente:<\/strong> Recomenda-se que os pacientes e os m\u00e9dicos respons\u00e1veis pelo tratamento entrem em contato com o Prof. Julien Haroche para obter mais informa\u00e7\u00f5es.<\/p>\n<p><strong>Identificador do ClinicalTrials.gov:<\/strong> NCT02089724<\/p>","protected":false},"excerpt":{"rendered":"<p>Study Objective: ECD patients with vemurafenib treatment seem to have a stable disease.&nbsp; This study evaluates the possibility of treatment interruption. Other BRAF inhibitors, such as dabrafenib, have recently been [&hellip;]<\/p>\n","protected":false},"featured_media":0,"parent":0,"menu_order":0,"template":"","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","cybocfi_hide_featured_image":"","wds_primary_study_trials_cat":0,"_links_to":"","_links_to_target":""},"study_trials_cat":[33],"class_list":["post-4424","study_trials","type-study_trials","status-publish","hentry","study_trials_cat-observational"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/pt\/wp-json\/wp\/v2\/study_trials\/4424","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/pt\/wp-json\/wp\/v2\/study_trials"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/pt\/wp-json\/wp\/v2\/types\/study_trials"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/pt\/wp-json\/wp\/v2\/media?parent=4424"}],"wp:term":[{"taxonomy":"study_trials_cat","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/pt\/wp-json\/wp\/v2\/study_trials_cat?post=4424"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}